Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Immune cell therapies and immune cell engineering

Original research

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer

Online download statistics by month:

Online download statistics by month: January 2022 to March 2024

	Abstract	Full	Pdf
Jan 2022	542	568	251
Feb 2022	252	261	123
Mar 2022	145	154	122
Apr 2022	115	122	93
May 2022	123	126	98
Jun 2022	141	155	108
Jul 2022	143	143	111
Aug 2022	144	147	85
Sep 2022	169	170	112
Oct 2022	196	198	93
Nov 2022	154	157	88
Dec 2022	152	152	58
Jan 2023	109	109	81
Feb 2023	147	153	109
Mar 2023	117	118	108
Apr 2023	146	147	131
May 2023	86	87	54
Jun 2023	117	118	63
Jul 2023	100	101	69
Aug 2023	133	134	78
Sep 2023	75	76	43
Oct 2023	78	78	78
Nov 2023	137	138	64
Dec 2023	102	104	61
Jan 2024	89	89	50
Feb 2024	133	133	69
Mar 2024	109	112	112
Total	3954	4050	2512